This approach operationalizes where, when, how much at the bedside and provides a reproducible scaffold for trials
Alex Cook: In this study, we saw that after two years, those taking a GLP-1 drug for obesity and without diabetes, experienced an average of $4,206 higher cost of care in their second year compared to like members not taking a GLP-1 drug for obesity
Patient-centered factors include comorbidities (established ASCVD or indicators of high-risk established kidney disease, or heart failure), the presence of a compelling need to minimize hypoglycemia, the need to promote weight loss or minimize weight gain, and cost [15, 17]
2 However, when phentermine is used in combination with lifestyle changes, more people maintain the 5 to 10% of body weight they lost
Semaglutide slows gastric emptying, particularly in the first 8-12 weeks of dose escalation